Press release STADA Health Report 2026: 82 percent of Europeans are open to AI playing a role in their healthcare - STADA Health Report 2026: independent, representative survey of 20 European countries shows that Artificial Intelligence (AI) is ...
STADA strengthens CHC local hero brand portfolio by acquiring Locobase derma line in Nordics - STADA strengthens Consumer Healthcare presence in Nordic countries by acquiring rights to Locobase® dermatology brand - Locobase® range of 17 products ...
Press Release Enzymatica and STADA sign partnership agreement for Germany and Austria - New partnership agreement covers thelaunch and distribution of Enzymatica’s ColdZyme® oral-spray technology in Germany and Austria - Alliance combines Enzymatica’s clinically documented medical device with ...
STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi - European Commission grants approval for Gotenfia®, a golimumab biosimilar to Simponi® that was developed by Bio-Thera and will be marketed by STADA ...
Golimumab biosimilar Gotenfia from STADA and Bio-Thera receives positive CHMP opinion - Positive opinion from European Medicines Agency supports approval for golimumab biosimilar Gotenfia® developed by Bio-Thera and to be marketed by STADA - ...
STADA obtains approvals to bring denosumab biosimilars in bone-health and oncology to patients in Europe - European Commission approves STADA’s Kefdensis® and Zvogra® denosumab biosimilars for all indications of reference medicines Prolia® and ...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. Press release ...
EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar - STADA announces EMA acceptance of Marketing Authorization Applications for AVT03, a proposed denosumab biosimilar to Prolia® (Bone Health) and Xgeva® (Oncology) - STADA holds marketing rights for AVT03 in Europe, as well ...
